Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with uncurable metastatic carcinoma, lymphoma, or sarcoma.~* ECOG performance status 0, 1, 2~* No active bleeding~* No clinical coagulopathy~* Anticipated lifespan greater than 12 weeks~Exclusion Criteria:~* Active residual toxicity from prior therapies~* Active Infection~* HIV positive~* Hepatitis B or C positive~* Pregnant or nursing women~* Requirement for oral steroids~* Brain metastases~* Presence or history of autoimmune disease~* Shellfish or tetanus allergy~* Splenomegaly~* Lymph nodes greater than 10 cm in maximal diameter~* Uncontrolled angina or class II or IV heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KLH + anti-OX40 (Type: EXPERIMENTAL): Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
- Tetanus vaccine + anti-OX40 (Type: EXPERIMENTAL): Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH

Based on this trial design, predict the completion outcome and termination type (if applicable).